Ceribell to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
Ceribell (Nasdaq: CBLL), a medical technology company specializing in neurological condition diagnostics, has announced its upcoming financial results release. The company will disclose its fourth quarter and full year 2024 financial results after market close on February 25, 2025.
Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on the same day. Investors can participate by dialing (800) 715-9871 (domestic) or (646) 307-1963 (international) with access code 3782735. A webcast will be available live and archived in the Investor Relations section of Ceribell's website.
Ceribell (Nasdaq: CBLL), un'azienda di tecnologia medica specializzata nella diagnosi di condizioni neurologiche, ha annunciato il rilascio dei suoi risultati finanziari imminenti. L'azienda diffuserà i suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 dopo la chiusura del mercato il 25 febbraio 2025.
Il management terrà una teleconferenza alle 1:30 p.m. PT / 4:30 p.m. ET nello stesso giorno. Gli investitori possono partecipare componendo il numero (800) 715-9871 (nazionale) o (646) 307-1963 (internazionale) con il codice di accesso 3782735. Sarà disponibile un webcast in diretta e archiviato nella sezione Relazioni con gli Investitori del sito web di Ceribell.
Ceribell (Nasdaq: CBLL), una compañía de tecnología médica especializada en diagnósticos de condiciones neurológicas, ha anunciado la próxima publicación de sus resultados financieros. La compañía divulgará sus resultados financieros del cuarto trimestre y del año completo 2024 después del cierre del mercado el 25 de febrero de 2025.
La dirección llevará a cabo una llamada de conferencia a las 1:30 p.m. PT / 4:30 p.m. ET el mismo día. Los inversores pueden participar llamando al (800) 715-9871 (nacional) o al (646) 307-1963 (internacional) con el código de acceso 3782735. Se dispondrá de una transmisión en vivo y una grabación en la sección de Relaciones con Inversores del sitio web de Ceribell.
Ceribell (Nasdaq: CBLL)는 신경학적 질환 진단에 특화된 의료 기술 회사로, 곧 재무 결과가 발표될 것이라고 밝혔습니다. 이 회사는 2024년 4분기와 연간 전체 재무 결과를 2025년 2월 25일 장 마감 후에 공개할 예정입니다.
경영진은 같은 날 오후 1시 30분 PT / 오후 4시 30분 ET에 컨퍼런스 콜을 진행할 것입니다. 투자자들은 (800) 715-9871 (국내) 또는 (646) 307-1963 (국제)에 전화하여 액세스 코드 3782735를 입력하여 참여할 수 있습니다. Ceribell의 웹사이트 투자자 관계 섹션에서 실시간 방송 및 아카이브도 제공될 예정입니다.
Ceribell (Nasdaq: CBLL), une entreprise de technologie médicale spécialisée dans le diagnostic des troubles neurologiques, a annoncé la prochaine publication de ses résultats financiers. L'entreprise dévoilera ses résultats financiers du quatrième trimestre et de l'année entière 2024 après la clôture du marché le 25 février 2025.
La direction animera une conférence téléphonique à 13h30 PT / 16h30 ET le même jour. Les investisseurs peuvent participer en composant le (800) 715-9871 (national) ou le (646) 307-1963 (international) avec le code d'accès 3782735. Un webinaire sera disponible en direct et archivé dans la section Relations investisseurs du site web de Ceribell.
Ceribell (Nasdaq: CBLL), ein Medizintechnikunternehmen, das sich auf die Diagnostik neurologischer Erkrankungen spezialisiert hat, hat die bevorstehende Veröffentlichung seiner Finanzzahlen angekündigt. Das Unternehmen wird seine Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2024 nach Marktschluss am 25. Februar 2025 veröffentlichen.
Das Management wird am selben Tag um 13:30 Uhr PT / 16:30 Uhr ET eine Telefonkonferenz abhalten. Investoren können teilnehmen, indem sie (800) 715-9871 (national) oder (646) 307-1963 (international) mit dem Zugangscode 3782735 anrufen. Eine Live-Übertragung wird verfügbar sein und im Bereich für Investorenbeziehungen auf der Website von Ceribell archiviert.
- None.
- None.
SUNNYVALE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the fourth quarter and full year of 2024 after the close of trading on Tuesday, February 25, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on February 25, 2025.
Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 3782735. A live and archived webcast of the event will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/.
About CeriBell, Inc.
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA 510(k) cleared for indicating suspected seizure activity and currently utilized in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.
Investor Contact
Brian Johnston or Laine Morgan
Gilmartin Group
Investors@ceribell.com
Media Contact
Corrie Rose
Press@ceribell.com
FAQ
When will Ceribell (CBLL) release Q4 and full year 2024 earnings?
How can investors join Ceribell's (CBLL) Q4 2024 earnings call?
What time is Ceribell's (CBLL) Q4 2024 earnings conference call?
Where can I access the webcast of Ceribell's (CBLL) Q4 2024 earnings call?
